Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2026-01-01 @ 5:20 PM
Study NCT ID:
NCT05113693
Status:
COMPLETED
Last Update Posted:
2023-06-09
First Post:
2021-10-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C546215', 'term': 'lobeglitazone'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 33}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-11-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-06', 'completionDateStruct': {'date': '2021-12-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-06-07', 'studyFirstSubmitDate': '2021-10-28', 'studyFirstSubmitQcDate': '2021-10-28', 'lastUpdatePostDateStruct': {'date': '2023-06-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-11-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'AUCt of CKD-501, D759, H053', 'timeFrame': 'Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour', 'description': 'AUCt: Area under the concentration-time curve from time zero to time'}, {'measure': 'Cmax of CKD-501, D759, H053', 'timeFrame': 'Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour', 'description': 'Cmax: Maximum plasma concentration of the drug'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Type 2 Diabetes']}, 'descriptionModule': {'briefSummary': 'Objective\n\n\\- Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '54 Years', 'minimumAge': '19 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Healthy adult volunteers aged 19 ≤ \\~ \\< 55-year-old.\n2. Weight ≥55kg (man) or 45kg (woman), with calculated body mass index (BMI) of 17.5 ≤ \\~ \\< 30.5 kg/m2.\n3. Those who have no congenital diseases or chronic diseases within 3 years and have no abnormal symptoms or findings.\n4. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.\n6. Those who agree to contraception until the 1 month after last administration of clinical trial drugs.\n7. Those who have the ability and willingness to participate during the entire clinical trail.\n\nExclusion Criteria:\n\n1. Those who have clinically significant disease or medical history of heart failure, Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction, galactose intolerance, glucose-galactose malabsorption. And Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial.\n2. Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug.\n3. Those who have the test results written below\n\n * AST, ALT \\> 2 times higher than upper normal level\n4. Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before the first administration of investigational drug.\n\n * Beer 1 glass(250ml, Alcohol contents 5%) = 10g\n * Soju 1 glass(50ml, Alcohol contents 20%) = 8g\n * Wine 1 glass(125ml, Alcohol contents 12%) = 12g\n5. Those who exceeding smoking criteria(20 cigarettes/day) within 6 months before the first administration of investigational drug.\n6. Those who received investigational durg by participating in other clinical trial within 6 months before the first administration of investigational drug.\n7. Those who have vital sign written below\n\n * systolic blood pressure ≥140 mmHg or \\< 90 mmHg\n * diastolic blood pressure ≥ 90 mmHg or \\< 60 mmHg\n8. Those who have a drug or alcohol abuse history within 1 year before the first administration of investigational drug.\n9. Those who take barbiturate and related (causing induction or inhibition. of metabolism) drug within 30 days before the first administration of investigational drug.\n10. Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days before the first administration of investigational drug.\n11. Those who donated whole blood within 2 months or apheresis within 1 month before the first administration of investigational drug.\n12. Those who severe acute/chronic medical or mental condition which can increase the safety risk by administration of investigational drug.\n13. Those who have history of hypersensitivity to active pharmaceutical ingredient or additives.\n14. Those who are pregnant or breastfeeding.\n15. Those who can't ingest a high fat diet.\n16. Those who are deemed inappropriate to participate in clinical trial by investigators."}, 'identificationModule': {'nctId': 'NCT05113693', 'briefTitle': 'Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393', 'organization': {'class': 'INDUSTRY', 'fullName': 'Chong Kun Dang Pharmaceutical'}, 'officialTitle': 'A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions', 'orgStudyIdInfo': {'id': 'A98_05BE2118'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.\n\nPeriod 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition.', 'interventionNames': ['Drug: CKD-393', 'Drug: CKD-501, D759, H053']}, {'type': 'EXPERIMENTAL', 'label': '2', 'description': 'Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition.\n\nPeriod 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.', 'interventionNames': ['Drug: CKD-393', 'Drug: CKD-501, D759, H053']}], 'interventions': [{'name': 'CKD-393', 'type': 'DRUG', 'description': 'QD, PO', 'armGroupLabels': ['1', '2']}, {'name': 'CKD-501, D759, H053', 'type': 'DRUG', 'description': 'QD, PO', 'armGroupLabels': ['1', '2']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Jeonju', 'country': 'South Korea', 'facility': 'Chonbuk National University Hospital', 'geoPoint': {'lat': 35.82194, 'lon': 127.14889}}], 'overallOfficials': [{'name': 'Min Gul Kim, M.D, Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Chonbuk National University Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chong Kun Dang Pharmaceutical', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}